Abstract:Introduction. An effective way to reduce the volume of infusion (restrictive strategy) in hypovolemic shock, in particular in burn shock, is invasive hemodynamic monitoring and choosing the appropriate regimen for the use of inotropic agents, considering the data obtained. However, the use of inotropic agents in hypovolemic shock is still controversial. The most cutting issue is the choice of effective doses of inotropic agents. Aim. Justification of the need to use inotropic agents and assessment of the safety and effectiveness of dobutamine use in burn shock. Materials and methods. The pilot clinical study conducted in 2021–2022 included 9 patients aged 15–70 years who were admitted to the intensive care unit (ICU) of the Burn Center of the Novosibirsk State Regional Clinical Hospital with a total body surface area burned > 40% (II–III degree), in most cases – thermal inhalation injury, who were in the ICU for over 3 days. Intensive care of burn injury in the acute phase was performed according to conventional clinical recommendations. Myocardial samples for morphological and immunohistochemical studies were taken from 34 patients who died from burn shock (27 men and 7 women, aged from 21 to 51 years) from 2015 to 2019. The samples were taken post mortem, and with minimal atherosclerotic changes of the coronary arteries (lesions no more than 20–25%). The control group for morphological and immunohistochemical studies comprised samples which were taken from 25 individuals who died because of sudden circulatory arrest (19 men, 6 women). Results. Studies have shown a decrease in myocardial contractility in patients with burn shock. Morphological examination revealed contraction lesions of individual cardiomyocytes of varying degree, as well as foci of primary clumping of myofibrils’ cytoplasm and myocytolysis. The immunohistochemical study of myocardial sections showed a decrease in the actin expression by 2.4 times (p < 0.05) and desmin – by 2 times (p < 0.05) in comparison with the control group. The results of the clinical study showed that dobutamine at a rate of up to 5.0 μg/kg/min does not cause an arrhythmogenic effect and/or lactic acidosis. Conclusion. The data obtained on structural changes of the myocardium confirm the need for the use of inotropic agent in burn shock. Dobutamine at a rate of up to 5.0 μg/kg/min allows for a restrictive strategy of fluid resuscitation and rapid recovery from burn shock.

Low-dose dobutamine in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (the DOBERMANN-D trial): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial

Interleukin-6 receptor antibodies (tocilizumab) in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (DOBERMANN-T): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial

Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.

Effectiveness of Anisodamine for the Treatment of Critically Ill Patients with Septic Shock (acidosis Study): Study Protocol for Randomized Controlled Trial

Prognostic Performance of the IABP-SHOCK II Risk Score Among Cardiogenic Shock Subtypes in the Critical Care Cardiology Trials Network Registry

Milrinone vs Dobutamine for the Management of Cardiogenic Shock: Implications of Renal Function and Injury

Clinical and morphological justification of dobutamine use in burn shock

Early risk stratification of patients with acute myocardial infarction complicated by severe cardiogenic shock - The ECLS-SHOCK Risk Score

Cangrelor versus crushed ticagrelor in patients with acute myocardial infarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial

A Risk Stratification Scheme for In-Hospital Cardiogenic Shock in Patients With Acute Myocardial Infarction

Decoding cardiogenic shock: assessing shock index and its variants as prognostic indicators for in‐hospital mortality

Improved mortality and haemodynamics with milrinone in cardiogenic shock due to acute decompensated heart failure

Hemodynamic Management of Cardiogenic Shock in the Intensive Care Unit

American Heart Association Cardiogenic Shock Registry: Design and Implementation

Hemodynamic phenotype-based, capillary refill time-targeted resuscitation in early septic shock: The ANDROMEDA-SHOCK-2 Randomized Clinical Trial study protocol

Comparison of Outcomes Between Milrinone and Dobutamine in Patients With Cardiogenic Shock: A Meta-Analysis of Randomized Control Trials and Observational Studies

Clinical Characteristics, Management and Outcomes in Cardiogenic Shock: insights from a high-volume Italian Cardiac Intensive Care Unit

Baseline heart rate as a key prognostic indicator in AMI patients with cardiogenic shock undergoing successful primary PCI

Levosimendan in patients with cardiogenic shock refractory to dobutamine weaning

Safety and efficacy of up to 60 h of iv istaroxime in pre‐cardiogenic shock patients: Design of the SEISMiC trial

Identifying and Mitigating Risk of Post-Cardiotomy Cardiogenic Shock in Patients with Ischemic and Non-Ischemic Cardiomyopathy